Renaissance Capital logo

Neurogene (Aquinox)

Priced, Nasdaq: NGNE

Early-stage biotech developing treatments for inflammation of the lung and bladder.

Industry: Health Care

First Day Return: +8.6%

Early-stage biotech developing treatments for inflammation of the lung and bladder.
IPO Data
IPO Date 03/06/2014
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $46
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Vancouver, Canada
Founded 2003
Employees at IPO 12
Website www.aqxpharma.com

Neurogene (Aquinox) (NGNE) Performance

NGNE vs. IPO Index (IPOUSA)